The Role of Radioprotector Agents in the Protection of Normal tissue

Emamgholizadeh Minaei, Soraya; Hoseini, Farideh

doi:10.52547/rabms.7.3.161

Volume 7, Issue 3 (12-2021) Journal of Research in Applied and Basic Medical Sciences 2021, 7(3): 161-171 | Back to browse issues page

‎ 10.52547/rabms.7.3.161

Mendeley

Zotero

RefWorks

Emamgholizadeh Minaei S, Hoseini F. The Role of Radioprotector Agents in the Protection of Normal tissue. Journal of Research in Applied and Basic Medical Sciences 2021; 7 (3) :161-171
URL: http://ijrabms.umsu.ac.ir/article-1-115-en.html

The Role of Radioprotector Agents in the Protection of Normal tissue

Soraya Emamgholizadeh Minaei ^*

, Farideh Hoseini

Department of Medical Physics and Imaging, Urmia University of Medical Sciences, Urmia, Iran , minayee.s@gmail.com

Abstract: (1347 Views)

The role of radioprotectors to reduce the cellular damage induced by ionizing radiation has been studied in human, animal and in vitro culture models. Radiation therapy cannot eradicate tumors successfully because of soft tissue damage. Proper use of radioprotective agents (before or shortly after radiation) can reduce normal tissue radiation toxicity and improve treatment output. There are three groups of radioprotectors: Synthetic protectors, antioxidant nutrients, and Immunomodulators. We discussed the radioprotective efficacy and its interaction against toxic agents. In addition, we discussed articles that have used radioprotective agents in the treatment of cancer with radiotherapy to protect normal tissue.

Keywords: Radio protectors, Free radical, Antioxidant, Toxic substances, Radical scavenger

Full-Text [PDF 459 kb] (825 Downloads)

Type of Study: review article | Subject: General

References

1. Hosseinimehr SJ. Flavonoids and genomic instability induced by ionizing radiation. Drug Discov Today 2010;15(21-22):907-18. [DOI:10.1016/j.drudis.2010.09.005]

2. Hunter N, Muirhead CR. Review of relative biological effectiveness dependence on linear energy transfer for low-LET radiations. J Radiol Prot 2009;29(1):5. [DOI:10.1088/0952-4746/29/1/R01]

3. Mozdarani H. Radioprotective Properties of Histamine H 2 Receptor Antagonists: present and future prospects. J Radiat Res 2003;44(2):145-9. [DOI:10.1269/jrr.44.145]

4. Singh VK, Yadav VS. Role of cytokines and growth factors in radioprotection. Exp Mol Pathol 2005;78(2):156-69. [DOI:10.1016/j.yexmp.2004.10.003]

5. Bicker U, Friedberg K, Hebold G, Mengel K. Reduction of acute toxicity of cyclophosphamide and X-rays by the new immunomodulating compound BM 12.531. Experientia 1979;35(10):1361-3. [DOI:10.1007/BF01964009]

6. Cassatt DR, Fazenbaker CA, Bachy CM, Hanson MS, editors. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Seminars in radiation oncology: Elsevier; 2002. [DOI:10.1053/srao.2002.31382]

7. Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, Mitchell JB. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 2010;15(4):360-71. [DOI:10.1634/theoncologist.2009-S104]

8. Schmidt-Ullrich RK. Molecular targets in radiation oncology. Oncogene 2003;22(37):5730. [DOI:10.1038/sj.onc.1206662]

9. Harborne JB, Williams CA. Advances in flavonoid research since 1992. phytochemistry 2000;55(6):481-504. [DOI:10.1016/S0031-9422(00)00235-1]

10. Brown DQ, Pittock III JW, Rubinstein JS. Early results of the screening program for radioprotectors. Int J Radiat Oncol Biol Phys 1982;8(3-4):565-70. [DOI:10.1016/0360-3016(82)90685-X]

11. Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug Discov Today 2007;12(19-20):794-805. [DOI:10.1016/j.drudis.2007.07.017]

12. Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000;18(11):2226-33. [DOI:10.1200/JCO.2000.18.11.2226]

13. Livesey JC, Reed DJ. Chemical protection against ionizing radiation. Adv Radiat Biol 1987;13:285-353. [DOI:10.1016/B978-0-12-035413-9.50010-8]

14. Maisin J-R. Bacq and Alexander award lecture chemical radioprotection: past, present and future prospects. Int J Radiat Biol 1998;73(4):443-50. [DOI:10.1080/095530098142284]

15. Held KD, Biaglow JE. Mechanisms for the oxygen radical-mediated toxicity of various thiol-containing compounds in cultured mammalian cells. Radiat Res 1994;139(1):15-23. [DOI:10.2307/3578727]

16. Song J-Y, Han S-K, Bae K-G, Lim D-S, Son S-J, Jung I-S, et al. Radioprotective effects of ginsan, an immunomodulator. Radiat Res 2003;159(6):768-74. [DOI:10.1667/0033-7587(2003)159[0768:REOGAI]2.0.CO;2]

17. Patchen ML. Immunomodulators and hemopoiesis. Surv Immunol Res 1983;2(3):237-42. [DOI:10.1007/BF02918420]

18. Ainsworth E, Larsen R, Mitchell F, Taylor J. Survival-Promoting Effects of Endotoxin in Mice, Dogs, and Sheep. Naval Radiological Defense Lab., San Francisco; 1970. [Google Scholar]

19. Stickney DR, Dowding C, Garsd A, Ahlem C, Whitnall M, McKeon M, et al. 5-androstenediol stimulates multilineage hematopoiesis in rhesus monkeys with radiation-induced myelosuppression. Int Immunopharmacol 2006;6(11):1706-13. [DOI:10.1016/j.intimp.2006.07.005]

20. Stickney DR, Dowding C, Authier S, Garsd A, Onizuka-Handa N, Reading C, et al. 5-androstenediol improves survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression. Int Immunopharmacol 2007;7(4):500-5. [DOI:10.1016/j.intimp.2006.12.005]

21. Milas L, Hunter N, Ito H, Peters LJ. In vivo radioprotective activities of diethyldithiocarbamate (DDC). Int J Radiat Oncol Biol Phys 1984;10(12):2335-43. [DOI:10.1016/0360-3016(84)90242-6]

22. Aruoma OI. Free radicals, oxidative stress, and antioxidants in human health and disease. J Am Oil Chem Soc 1998;75(2):199-212. [DOI:10.1007/s11746-998-0032-9]

23. Seed T, Kumar S, Whitnall M, Srinivasan V, Singh V, Elliott T, et al. New strategies for the prevention of radiation injury: possible implications for countering radiation hazards of long-term space travel. J Radiat Res 2002;43(S):S239-S44. [DOI:10.1269/jrr.43.S239]

24. Satyamitra M, Devi PU, Murase H, Kagiya VT. In vivo radioprotection by α-TMG: preliminary studies. Mutat Res 2001;479(1-2):53-61. [DOI:10.1016/S0027-5107(01)00135-X]

25. Reiter RJ, Tan D-X, Herman TS, Thomas Jr CR. Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys 2004;59(3):639-53. [DOI:10.1016/j.ijrobp.2004.02.006]

26. Devi PU, Ganasoundari A, Rao B, Srinivasan K. In vivo radioprotection by ocimum flavonoids: survival of mice. Radiat Res 1999;151(1):74-8. [DOI:10.2307/3579750]

27. Uma Devi P, Ganasoundari A, Vrinda B, Srinivasan K, Unnikrishnan M. Radiation protection by the ocimum flavonoids orientin and vicenin: mechanisms of action. Radiat Res 2000;154(4):455-60. [DOI:10.1667/0033-7587(2000)154[0455:RPBTOF]2.0.CO;2]

28. Landauer MR, Srinivasan V, Seed TM. Genistein treatment protects mice from ionizing radiation injury. J Appl Toxicol 2003;23(6):379-85. [DOI:10.1002/jat.904]

29. Cavallo A, Hassan M. Stability of melatonin in aqueous solution. J Pineal Res 1995;18(2):90-2. [DOI:10.1111/j.1600-079X.1995.tb00145.x]

30. Snyder SH, Axelrod J, Zweig M. Circadian rhythm in the serotonin content of the rat pineal gland: regulating factors. J Pharmacol Exp Ther 1967;158(2):206-13. [Google Scholar]

31. Claustrat B, Geoffriau M, Brun J, Chazot G. Melatonin in humans: a biochemical marker of the circadian clock and an endogenous synchronizer. Neurophysiol Clin 1995;25(6):351-9. [DOI:10.1016/0987-7053(96)84908-2]

32. Reiter RJ, Herman TS, Meltz ML. Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers. Mutat Res 1996;371(3-4):221-8. [DOI:10.1016/S0165-1218(96)90110-X]

33. Shirazi A, Mihandoost E, Ghobadi G, Mohseni M, Ghazi-Khansari M. Evaluation of radio-protective effect of melatonin on whole body irradiation induced liver tissue damage. Cell J Yakhteh 2013;14(4):292. [Google Scholar]

34. Blickenstaff RT, Brandstadter SM, Reddy S, Witt R. Potential radioprotective agents. 1. Homologs of melatonin. J Pharm Sci 1994;83(2):216-8. [DOI:10.1002/jps.2600830220]

35. Hahn SM, Sullivan FJ, DeLuca AM, Krishna CM, Wersto N, Venzon D, et al. Evaluation of tempol radioprotection in a murine tumor model. Free Radic Biol Med 1997;22(7):1211-6. [DOI:10.1016/S0891-5849(96)00556-4]

36. Chung SI, Smart DK, Chung EJ, Citrin DE. Radioprotection as a method to enhance the therapeutic ratio of radiotherapy. Increasing the therapeutic ratio of radiotherapy: Springer; 2017. p. 79-102. [DOI:10.1007/978-3-319-40854-5_4]

37. Kamran MZ, Ranjan A, Kaur N, Sur S, Tandon V. Radioprotective agents: strategies and translational advances. Med Res Rev 2016;36(3):461-93. [DOI:10.1002/med.21386]

38. Mitchell JB, DeGraff W, Kaufman D, Krishna MC, Samuni A, Finkelstein E, et al. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch Biochem Biophys 1991;289(1):62-70. [DOI:10.1016/0003-9861(91)90442-L]

39. Del Bano M, Castillo J, Benavente-García O, Lorente J, Martín-Gil R, Acevedo C, et al. Radioprotective− Antimutagenic Effects of Rosemary Phenolics against Chromosomal Damage Induced in Human Lymphocytes by γ-rays. J Agric Food Chem 2006;54(6):2064-8. [DOI:10.1021/jf0581574]

40. Soyal D, Jindal A, Singh I, Goyal P. Protective capacity of Rosemary extract against radiation induced hepatic injury in mice. Int J Radiat Res 2007; 4(4): 161-8. [Google Scholar]

41. Jindal A, Soyal D, Sancheti G, Goyal PK. Radioprotective potential of Rosemarinus officinalis against lethal effects of gamma radiation: a preliminary study. J Environ Pathol Toxicol Oncol 2006;25(4):633-42. [DOI:10.1615/JEnvironPatholToxicolOncol.v25.i4.30]

42. Zangeneh M, Mozdarani H, Mahmoudzadeh A. Potent radioprotective effects of combined regimens of famotidine and vitamin C against radiation-induced micronuclei in mouse bone marrow erythrocytes. Radiat Environ Biophys 2015;54(2):175-81. [DOI:10.1007/s00411-015-0586-5]

43. Mortazavi S, Rahimi S, Mosleh-Shirazi M, Arjomandi M, Soleimani A, Hossein-Abadi OK, et al. A comparative study on the life-saving radioprotective effects of vitamins a, E, C and over-the-counter multivitamins. Journal of biomedical physics & engineering. 2015;5(2):59. [PMCID]

44. El-Nahas SM, Mattar FE, Mohamed AA. Radioprotective effect of vitamins C and E. Mutat Res Lett 1993;301(2):143-7. [DOI:10.1016/0165-7992(93)90037-V]

45. Felemovicius I, Bonsack ME, Baptista ML, Delaney JP. Intestinal radioprotection by vitamin E (alpha-tocopherol). Ann Surg 1995;222(4):504. [DOI:10.1097/00000658-199522240-00008]

46. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999;91(4):317-31. [DOI:10.1093/jnci/91.4.317]

47. Srinivasan M, Sudheer AR, Pillai KR, Kumar PR, Sudhakaran P, Menon V. Lycopene as a natural protector against γ-radiation induced DNA damage, lipid peroxidation and antioxidant status in primary culture of isolated rat hepatocytes in vitro. Biochim Biophys Acta 2007;1770(4):659-65. [DOI:10.1016/j.bbagen.2006.11.008]

48. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 1989;274(2):532-8. [DOI:10.1016/0003-9861(89)90467-0]

49. Srinivasan M, Devipriya N, Kalpana K, Menon VP. Lycopene: an antioxidant and radioprotector against γ-radiation-induced cellular damages in cultured human lymphocytes. Toxicology 2009;262(1):43-9. [DOI:10.1016/j.tox.2009.05.004]

50. Çavuşoğlu K, Yalçın E. Radioprotective effect of lycopene on chromosomal aberrations (CAs) induced by gamma radiation in human lymphocytes. J Environ Biol 2009;30(1):113-7. [Google Scholar]

51. Lapenna D, De Gioia S, Mezzetti A, Grossi L, Festi D, Marzio L, et al. H2‐receptor antagonists are scavengers of oxygen radicals. Eur J Clin Invest 1994;24(7):476-81. [DOI:10.1111/j.1365-2362.1994.tb02378.x]

52. Gifford R. Cimetidine induced augmentation of cell mediated cytotoxicity following in vitro and in vivo treatment. Fed, Pro 1983;39:924. [Google Scholar]

53. Mozdarani H, Khoshbin-Khoshnazar AR. In vivo protection by cimetidine against fast neutron-induced micronuclei in mouse bone marrow cells. Cancer Lett 1998;124(1):65-71. [DOI:10.1016/S0304-3835(97)00451-5]

54. Mozdarani H, Nasirian B, Haeri A. In vivo γ-rays induced initial DNA damage and the effect of famotidine in mouse leukocytes as assayed by the alkaline comet assay. J Radiat Res 2007;48(2):129-34. [DOI:10.1269/jrr.06055]

55. Mozdarani H, Salimi M, Froughizadeh M. Effect of cimetidine and famotidine on survival of lethally gamma irradiated mice. Iran J Radiat Res 2008;5(4):187-94. [Google Scholar]

56. Razzaghdoust A, Mozdarani H, Mofid B. Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy. Strahlenther Onkol 2014;190(8):739-44. [DOI:10.1007/s00066-014-0602-8]

57. Davidson D. Secncy TR: Biological characterization of some improved Radioprotector. ln: Brady LW (cd). Radiation Sensitizers; Their Use in the Clinical Management of Cancer. New York: Masson; 1980. [Google Scholar]

58. Brizel D, Wasserman T, Strnad V, Wannemacher M, Henke M, Monnier A, et al. 6 Final report of a phase III randomized trial of amifostine as a radioprotectant in head and neck cancer. Int J Radiat Oncol Biol Phys 1999;45(3):147-8. [DOI:10.1016/S0360-3016(99)90024-X]

59. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18(19):3339-45. [DOI:10.1200/JCO.2000.18.19.3339]